Dapagliflozin + Sitagliptin
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
No
Active ingredients: Dapagliflozin | Sitagliptin
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
01/07/2022 Sitagliptin for treating type 2 diabetes mellitus (opens in new tab)
The Ministry of Health’s Drug Advisory Committee has recommended:
sitagliptin 25 mg, 50 mg and 100 mg tablets
in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.
Subsidy status
[R] Sitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
[NR] SDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.
Post Marketing Information
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Oral
* Clinical information is available for this product.